PanTher Therapeutics

Powered by its proprietary Sagittari™ platform, PanTher Therapeutics is a pioneering biotechnology company focused on revolutionizing localized cancer treatment. The Sagittari™ platform facilitates the continuous, high-dose delivery of potent oncology agents exclusively at the tumor site, offering a groundbreaking solution for the targeted administration of therapeutic agents. Founded in 2016 by its CEO, who is also the inventor of the foundational technology at the Massachusetts Institute of Technology, the company has made significant strides in its clinical development. PanTher’s lead clinical candidate, PTM-101, has shown promise in a Phase 1 clinical trial for localized non-metastatic pancreatic cancer patients. The company’s innovative approach has attracted MedTech Innovator as a supporter, with the latest non-equity assistance investment in June 6, 2023. With its headquarters in the United States, PanTher is poised to expand its transformative technology to address additional solid tumor indications. With its commitment to advancing the fight against cancer, PanTher Therapeutics stands at the forefront of the biotechnology industry, representing a compelling opportunity for those seeking to invest in cutting-edge oncology solutions.